Predicting the tumorigenic phenotype of human bladder cancer cells by combining with fetal rat mesenchyme

Most bladder cancers are urothelial carcinomas. Roughly 75% of patients have nonmuscle invasive bladder cancer (NMIBC) and the remainder have muscle invasive or metastatic disease [1]. For all stages, the 5-year relative survival is around 70% to 80% [2]. The rate of recurrence in NMIBC ranges from 50% to 90%. In addition, 10% to 30% of NMIBC patients progress to muscle invasive bladder cancer (MIBC) requiring radical surgery [1]. In NMIBC patients after first transurethral resection, identification of the key predictors of progression should improve overall survival by supporting the use of aggressive treatment in short-term follow-up.

Source: Urologic Oncology: Seminars and Original Investigations - August 20, 2018 Category: Urology & Nephrology Authors: Manabu Miki, Kenichiro Ishii, Takeshi Sasaki, Manabu Kato, Shinya Kajiwara, Hideki Kanda, Kiminobu Arima, Yoshifumi Hirokawa, Masatoshi Watanabe, Yoshiki Sugimura Tags: Original Article Source Type: research